FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum
Rhea-AI Summary
FibroGen (Nasdaq: FGEN) rebranded as Kyntra Bio and will begin trading under the new Nasdaq symbol KYNB at market open on January 8, 2026. The company said the change reflects a sharpened focus on oncology and rare disease, centered on three mid/late‑stage assets: FG-3246 (CD46 ADC), FG-3180 (CD46 PET imaging), and roxadustat (Phase 3‑ready). Recent corporate milestones cited include sale of FibroGen China, payoff of the senior secured term loan, and extension of cash runway into 2028. Upcoming catalysts: FG-3246 topline data at ASCO GU in Q1 2026, FG-3180/FG-3246 Phase 2 interim readout in H2 2026, and an FDA Orphan Drug Designation plus a submitted Phase 3 protocol for roxadustat in MDS.
Positive
- Name change and new ticker KYNB may refresh investor attention
- Sale of FibroGen China completed, per company statement
- Senior secured term loan fully paid off
- Cash runway extended into 2028
- FG-3246 topline data expected at ASCO GU in Q1 2026
- Roxadustat received FDA Orphan Drug Designation in MDS
Negative
- Company strategy concentrated on three core assets
- Material clinical readouts (H1/H2 2026) are still pending
- Clinical and regulatory milestones will materially affect valuation
News Market Reaction – FGEN
On the day this news was published, FGEN gained 7.65%, reflecting a notable positive market reaction. Argus tracked a peak move of +2.8% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $39M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves, from -3.55% (RLMD) to +7.92% (PDSB), suggesting today’s rebranding story is more company-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 15 | Orphan designation | Positive | +19.8% | FDA Orphan Drug Designation for roxadustat in myelodysplastic syndromes. |
| Dec 02 | Conference appearance | Neutral | +0.5% | Planned presentation at Oppenheimer rare disease summit with catalyst-focused panel. |
| Nov 10 | Earnings & update | Neutral | -0.3% | Q3 2025 results with China sale, cash runway into 2028, and trial progress. |
| Nov 03 | Earnings preview | Neutral | -0.1% | Announcement of upcoming Q3 2025 results call and business update webcast. |
| Sep 24 | Clinical trial start | Positive | +3.4% | Initiation of Phase 2 monotherapy trial of FG‑3246 in mCRPC with FG‑3180 biomarker work. |
Recent clinically focused announcements, especially around roxadustat and FG-3246, have often seen positive price alignment, while broader financial updates have produced muted or slightly negative reactions.
Over the last few months, FibroGen has shifted toward an oncology and rare-disease profile supported by significant transactions and clinical milestones. The sale of FibroGen China and strengthened cash position, reported on Nov 10, 2025, funded a focus on FG‑3246 and roxadustat. Clinical updates, including a Phase 2 monotherapy launch in mCRPC on Sep 24, 2025 and Orphan Drug Designation for roxadustat on Dec 15, 2025, drew notably positive reactions. Today’s Kyntra Bio rebrand reinforces this ongoing strategic pivot.
Market Pulse Summary
The stock moved +7.7% in the session following this news. A strong positive reaction aligns with the company’s ongoing strategic repositioning. The rebrand to Kyntra Bio formalized an oncology and rare-disease focus already telegraphed by prior milestones such as FDA Orphan Drug Designation and initiation of a Phase 2 FG‑3246 trial. With shares at $9.02 and above the 200-day MA, investors may have viewed the cleaner story and stated runway into 2028 as incremental validation, though past rallies have sometimes followed single catalysts.
Key Terms
antibody drug conjugate medical
pet imaging agent medical
orphan drug designation regulatory
phase 2 medical
phase 3 medical
myelodysplastic syndromes medical
cusip financial
AI-generated analysis. Not financial advice.
- Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare disease
- Kyntra Bio will begin trading on Nasdaq under the trading symbol “KYNB” effective January 8th
SAN FRANCISCO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN), today announced it is rebranding the company to Kyntra Bio, representing the next step of the transformation of the Company and its focus on oncology and rare disease assets. The Company’s common stock will begin trading under the new Nasdaq symbol “KYNB” at stock market open on January 8, 2026.
“2025 was a transformational year, highlighted by the sale of FibroGen China, the payoff of our senior secured term loan, and the extension of our cash runway into 2028. We begin this year as Kyntra Bio, a name that captures our company journey and evolution and reflects our purposeful move to a company obsessed with creating outsized impact for patients and shareholders,” said Thane Wettig, Chief Executive Officer of Kyntra Bio. “Today, with a sharpened direction, Kyntra Bio is laser-focused on our mid- and late-stage assets – specifically, FG-3246, our first-in-class, CD46 targeting antibody drug conjugate, and FG-3180, our companion PET imaging agent, currently in a Phase 2 monotherapy trial in prostate cancer, and roxadustat, our Phase 3 ready asset, for which we recently received Orphan Drug Designation in myelodysplastic syndromes. We are thrilled to move forward with renewed purpose into this bold era for our company and are excited for what is in front of us.”
Recent Highlights and Upcoming Milestones
FG-3246 (CD46 Targeting ADC) and FG-3180 (CD46 Targeting PET Imaging Agent)
- Topline results from the investigator-sponsored Phase 1b/2 study, conducted by UCSF, of FG-3246 in combination with enzalutamide in patients with mCRPC are expected to be presented at ASCO GU in the first quarter of 2026.
- Interim results from the recently commenced Phase 2 monotherapy trial are expected in the second half of 2026. The trial will also assess the diagnostic performance of FG-3180 to determine the potential correlation between CD46 expression and response to FG-3246.
Roxadustat
- Granted Orphan Drug Designation from the FDA for the treatment of myelodysplastic syndromes (MDS).
- Submitted the pivotal Phase 3 clinical trial protocol for roxadustat for the treatment of anemia in patients with lower-risk MDS and high transfusion burden to the U.S. Food and Drug Administration.
In addition to the new name, the Company is refreshing its corporate website to better reflect the Company’s strategy moving forward. The CUSIP number for the Company’s common stock is not affected by the name change.
About Kyntra Bio
Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.kyntrabio.com.
Forward-Looking Statements
This release contains forward-looking statements regarding Kyntra Bio’s strategy, future plans and prospects, including statements regarding its commercial products and clinical programs and those of its collaboration partners Fortis and UCSF. These forward-looking statements include, but are not limited to, statements regarding the efficacy, safety, and potential clinical or commercial success of Kyntra Bio products and product candidates, statements under the caption “Recent Highlights and Upcoming Milestones”, statements about regulatory interactions, the payoff of the Morgan Stanley Tactical Value term loan, statements regarding cash, such as the expectation that cash, cash equivalents and accounts receivable will be sufficient to fund Kyntra Bio’s operating plans into 2028, and statements about Kyntra Bio’s plans and objectives. These forward-looking statements are typically identified by use of terms such as “may,” “will”, “should,” “on track,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. Kyntra Bio’s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in Kyntra Bio’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, each as filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Kyntra Bio undertakes no obligation to update any forward-looking statement in this press release, except as required by law.
For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@kyntrabio.com
FAQ
When will FibroGen begin trading as Kyntra Bio under the symbol KYNB?
What are Kyntra Bio's lead drug candidates and their stages (FGEN/KYNB)?
When are key clinical readouts for FG-3246 and FG-3180 expected for FGEN/KYNB investors?
What recent financial milestones did FibroGen report before rebranding to Kyntra Bio?
What regulatory progress has roxadustat achieved for myelodysplastic syndromes (MDS)?
